Igor Bilinsky - 17 Jan 2023 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role: Chief Operating Officer
Signature: /s/ Igor Bilinsky
Issuer symbol: IOVA
Transactions as of: 17 Jan 2023
Net transactions value: -$30,035
Form type: 4
Filing time: 19 Jan 2023, 15:52:06 UTC
Previous filing: 05 Jan 2023
Next filing: 06 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IOVA	Common Stock	Options Exercise	$0	+11,248	+63%	$0.000000	29,049	17 Jan 2023	Direct	F1
transaction	IOVA	Common Stock	Tax liability	$30,035	-4,671	-16%	$6.43	24,378	17 Jan 2023	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IOVA	Restricted Stock Units	Options Exercise	$0	-11,248	-33%	$0.000000	22,502	17 Jan 2023	Common stock	11,248		Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One-third of the restricted stock units ("RSUs") issued to the Reporting Person on January 14, 2022, vested on January 14, 2023. The vested RSUs were settled on January 17, 2023.
F2	Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities.
F3	Represents common stock remaining after deducting the common stock withheld for taxes.
F4	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F5	The remaining RSUs will vest in eight equal quarterly installments over the next two years.